Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359763 | 0.89 | DRD2 (0.41) | DRD2 | |
| SCHEMBL20377850 | 0.83 | CA1 (0.45) | DRD2CA1CA2ACHEALDH1A1 | |
| SCHEMBL2051051 | 0.83 | — | — | |
| SCHEMBL18380886 | 0.83 | CA1 (0.45) | DRD2CA1CA2ACHEALDH1A1 | |
| SCHEMBL18193485 | 0.82 | DRD2 (0.39) | DRD2CA1CA2ACHE | |
| SCHEMBL13888863 | 0.82 | SSTR4 (0.41) | DRD2KDM4EALDH1A1P2RX4 | |
| SCHEMBL12706448 | 0.79 | CA1 (0.40) | DRD2CA1CA2ACHE | |
| SCHEMBL10205129 | 0.79 | DRD2 (0.40) | DRD2ALDH1A1 | |
| SCHEMBL18705052 | 0.79 | ALDH1A1 (0.50) | DRD2ALDH1A1 | |
| SCHEMBL20328135 | 0.79 | EPHX1 (0.50) | DRD2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| EP-2069327-B1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | DRD2 2385/4885CA1 3573/4885CA2 2652/4885 |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | DRD2 3642/4885CA1 4784/4885CA2 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.